Last Updated on December 16, 2024 by The Health Master
Insulin Inhalation Powder
Cipla, a leading pharmaceutical company in India, has made significant strides in diabetes management by securing approval from the Central Drugs Standard Control Organisation (CDSCO) for the distribution and marketing of Afrezza inhalation powder (Insulin inhalation powder).
This innovative medication, developed by MannKind Corporation (USA), offers a groundbreaking approach to insulin delivery, addressing the needs of millions of people living with diabetes mellitus in India.
What is Insulin inhalation powder?
Insulin inhalation powder is a rapid-acting insulin that is inhaled rather than injected.
This unique delivery method offers several advantages over traditional insulin injections:
- Convenience: Insulin inhalation powder eliminates the need for multiple daily injections, making it a more convenient option for patients.
- Reduced Needle Fear: Many people with diabetes experience discomfort or anxiety associated with needle injections. Insulin inhalation powder provides a needle-free alternative.
- Rapid Action: Insulin inhalation powder starts working as early as 12 minutes, helping to control blood sugar levels quickly after meals.
How Does Insulin inhalation powder Work?
Insulin inhalation powder is inhaled through a small device, similar to an asthma inhaler.
The medication is rapidly absorbed into the lungs and enters the bloodstream, where it works to lower blood sugar levels.
Its effects typically last for 2-3 hours, closely mimicking the body’s natural insulin response.
Insulin inhalation powder for Type 1 and Type 2 Diabetes
Insulin inhalation powder is approved for use in both type 1 and type 2 diabetes mellitus.
It can be used in conjunction with other diabetes medications, such as oral medications or long-acting insulin.
Cipla’s Commitment to Diabetes Care
Cipla’s acquisition of Afrezza (Insulin inhalation powder) aligns with its mission to improve patient outcomes and access to innovative therapies.
By making this non-injectable insulin available in India, Cipla aims to empower people with diabetes to manage their condition more effectively and conveniently.
Key Takeaways
- Insulin inhalation powder is a revolutionary non-injectable insulin that offers a convenient and needle-free option for diabetes management.
- It is approved for both type 1 and type 2 diabetes.
- Insulin inhalation powder works rapidly and effectively to control blood sugar levels after meals.
- Cipla’s introduction of Insulin inhalation powder in India marks a significant step forward in diabetes care.
By providing a patient-centered solution, Cipla is empowering people with diabetes to take control of their health and improve their quality of life.
-
Is Insulin inhalation powder safe?
Insulin inhalation powder has undergone rigorous clinical trials and has been approved by regulatory authorities. It is generally safe and well-tolerated when used as prescribed.
-
How often should I use Insulin inhalation powder?
The frequency of Insulin inhalation powder use will depend on your individual treatment plan, which will be determined by your healthcare provider.
-
Are there any side effects of Insulin inhalation powder?
Common side effects of Insulin inhalation powder may include cough, throat irritation, and hypoglycemia (low blood sugar).
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.
CDSCO directs expedited Approval of Rare Disease Drugs and Medical Devices
CDSCO approves Robotic System for Telesurgery
CDSCO Panel approval granted for Anti Cancer Drug Pertuzumab
CDSCO approval granted for Anti Cancer Drug Olaparib
CDSCO Panel nod granted for Lumateperone Capsule
CDSCO Recruitment Rules for Medical Device Officers: A Closer Look
DCGI to inaugurate AIPAC Event: A Boon for Indian Pharmaceutical
Key Notes on Revised Schedule M: Point No. 5 – Qualification and validation
CDSCO directs expedited Approval of Rare Disease Drugs and Medical Devices
CDSCO approves Robotic System for Telesurgery
MN Sridhar has been appointed as Director of Drug Control Administration: Tamil Nadu
NPPA approves price increase for 11 Drugs
Four arrested for supplying Spurious Drugs to Maharashtra Hospital
Key Notes on Revised Schedule M: Point No. 4 – Sanitation and Hygiene
Wearable Medical device: The Future of Heart Health Monitoring
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
